ASIS Corporation
Quick facts
Phase 1 pipeline
- Adverse Reactions of Botox intramuscularly · Neurology
Botulinum toxin inhibits acetylcholine release at neuromuscular junctions - Adverse Reactions of Botox subdermally
- Adverse Reactions of Enbrel subcutaneously · Immunology
Tumor necrosis factor-alpha inhibitor - Adverse Reactions of Gammagard subcutaneously at Week 12
- Efficacy of Botox intramuscularly at Week 6
- Efficacy of Botox subdermally at Week 12
- Efficacy of Botox subdermally at Week 18
- Efficacy of Botox subdermally at Week 24
- Efficacy of Botox subdermally at Week 30
- Efficacy of Botox subdermally at Week 6
- Gadolinium For abdomen
- Gadolinium For lower back
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Related
- Sector hub: All tracked pharma companies